[Immune stimulation with G-CSF (Neupogen) in septic patients with immune paralysis]

Abstract

Ten patients with sepsis (HLA-DR+ monocytes < 30%) were treated with G-CSF (300 mg Filgrastin, Neupogen 30, Amgen). All patients showed a rise in HLA-DR+ monocytes during therapy. In six patients the high level of HLA-DR+ monocytes persisted after therapy; these patients survived. In the other four patients the number of HLA-DR+ monocytes declined after application of G-CSF, and the patients died of multiorgan failure. Some patients with sepsis might profit from immunestimulating therapy with G-CSF, but further studies are needed to prove whether or not this is true.